CHRM1 (Muscarinic Acetylcholine Receptor 1), also known as M1 muscarinic receptor, is a G protein-coupled receptor (GPCR) that mediates cholinergic signaling in the central nervous system. The receptor is encoded by the CHRM1 gene located on chromosome 11q12.1 and is predominantly coupled to the Gq/11 signaling pathway. As the most abundant muscarinic receptor subtype in the cortex and hippocampus, M1 receptors play critical roles in learning, memory, attention, and higher cognitive functions[1].
The cholinergic system has been central to Alzheimer's disease (AD) research since the seminal "cholinergic hypothesis" proposed in the early 1980s. The discovery of significant loss of cholinergic neurons in the basal forebrain of AD patients led to the development of acetylcholinesterase inhibitors as the first approved treatments for AD symptom management. M1 muscarinic receptors represent a complementary therapeutic target that acts downstream of the cholinergic system, potentially offering cognitive benefits while avoiding some limitations of acetylcholinesterase inhibitors[2][3].
| CHRM1 Protein | |
|---|---|
| Protein Name | Muscarinic acetylcholine receptor M1 |
| Gene | [CHRM1](/genes/chrm1) |
| UniProt | P11229 |
| Chromosome | 11q12.1 |
| Signal Transduction | Gq/11 → PLC → IP3/DAG → Ca2+/PKC |
| Primary Location | Cortex, hippocampus, basal forebrain |
| Function | Learning, memory, attention, cognition |
CHRM1 is a seven-transmembrane domain GPCR belonging to the class A (rhodopsin) family. The receptor consists of:
The orthosteric binding site is located within the transmembrane domain, accessible from the extracellular space. Acetylcholine binds in a pocket formed by the seven transmembrane helices, with key interactions involving conserved aspartate residues in TM2 and TM7.
CHRM1 is predominantly coupled to Gq/11 proteins, initiating the following cascade:
The M1-Gq signaling pathway activates multiple downstream effectors:
CHRM1 exhibits distinct pharmacological profiles for different ligand classes:
Agonists:
Antagonists:
Allosteric Modulators:
The development of selective agonists and positive allosteric modulators (PAMs) has been a major focus for AD drug development, as these compounds may provide cognitive benefits with improved safety profiles compared to nonselective agents[5][6].
M1 muscarinic receptors are densely distributed in brain regions critical for cognition:
The receptor is primarily located on postsynaptic neurons, where it mediates the effects of acetylcholine released from cholinergic projection neurons. However, presynaptic M1 receptors also exist on cholinergic terminals, where they may modulate acetylcholine release through feedback mechanisms.
Within neurons, M1 receptors are localized to:
Glial expression of M1 receptors has also been reported, particularly on astrocytes, where they may participate in neuron-glia communication and metabolic regulation.
M1 muscarinic receptors are essential for various forms of learning and memory:
Long-term potentiation (LTP) in the hippocampus, a cellular correlate of learning, requires M1 receptor activity:
Studies using M1 knockout mice demonstrate impaired LTP and spatial memory deficits, confirming the receptor's crucial role in hippocampal plasticity[7].
In the cortex, M1 receptors contribute to:
M1 receptor blockade (e.g., by scopolamine) produces acute cognitive impairment in humans and animals, demonstrating the receptor's ongoing role in cognition in the adult brain.
The intracellular pathways by which M1 receptors support memory include:
These pathways converge to enhance synaptic strength and support the formation of long-term memory traces.
Alzheimer's disease is characterized by progressive degeneration of cholinergic neurons in the basal forebrain:
Despite preserved M1 receptor numbers in early AD (relative to M2 receptor loss), the receptor's effectiveness is compromised by insufficient acetylcholine availability. This creates an opportunity for M1-selective agonists that can bypass the deficient endogenous neurotransmitter[8].
Aβ pathology interacts with muscarinic receptor signaling in several ways:
The relationship between M1 receptors and AD pathology suggests that M1 agonists could provide both symptomatic cognitive benefits and disease-modifying effects through neuroprotection[9][10].
M1 muscarinic receptor targeting in AD offers several potential benefits:
Symptomatic改善:
Disease-modifying potential:
Clinical trials of M1 agonists have shown mixed results, with some demonstrating cognitive benefits but limited by side effects related to peripheral muscarinic activation (salivation, sweating, gastrointestinal effects)[11].
While primarily considered an extrapyramidal movement disorder, Parkinson's disease involves significant cholinergic dysfunction:
M1 receptors in PD are relevant in several contexts:
Dyskinesias associated with levodopa treatment involve striatal cholinergic signaling:
Alpha-synuclein pathology affects muscarinic receptor function:
The cholinergic deficit in PD dementia is more severe than in PD without dementia:
M1 receptors are implicated in schizophrenia pathophysiology:
Cholinergic signaling through M1 receptors has anti-epileptic effects:
M1 receptors on oligodendrocytes may have roles in myelination:
While not directly targeting M1 receptors, approved AD treatments increase synaptic acetylcholine:
These drugs provide modest cognitive benefits but do not specifically address M1 receptor signaling.
Direct M1 agonist development has faced challenges:
The main limitation has been achieving central selectivity without peripheral side effects.
PAMs offer a potentially safer approach:
PAMs offer advantages:
While counterintuitive for cognitive enhancement, M1 antagonists have uses:
Peripheral muscarinic side effects limit M1 agonist utility:
Central side effects:
These side effects can be mitigated by:
Bonner TI, et al. Cloning and expression of the human muscarinic acetylcholine receptor gene. Neuron. 1991. ↩︎
Coyle JT, et al. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983. ↩︎
Conn PJ, et al. Muscarinic acetylcholine receptors: novel therapeutic opportunities in Alzheimer's disease. Discovery Medicine. 2009. ↩︎
Hedrington MS, et al. Muscarinic receptor subtypes in the central nervous system: implications for drug discovery and development. Pharmacology Reviews. 2018. ↩︎
Fisher A, et al. M1 muscarinic agonists for the treatment of Alzheimer's disease: novel therapies for an old target. Journal of Alzheimer's Disease. 2012. ↩︎
Turlington JS, et al. Discovery of selective M1 muscarinic receptor agonists as cognition enhancers. Journal of Medicinal Chemistry. 2019. ↩︎
Mitsushima D, et al. M1 muscarinic receptors are required for long-term potentiation in the hippocampus. Learning and Memory. 2019. ↩︎
Schliebs R, et al. Muscarinic acetylcholine receptors in the pathogenesis of Alzheimer's disease. Current Alzheimer Research. 2011. ↩︎
Berthoud HR, et al. Muscarinic receptors modulating amyloid processing and synaptic plasticity in Alzheimer's disease. Neuropharmacology. 2019. ↩︎
B建国, et al. Cholinergic signaling and tau pathology in Alzheimer's disease. Journal of Neurochemistry. 2019. ↩︎
Chen Y, et al. M1 muscarinic receptor signaling in amyloid-beta mediated neurodegeneration. Cellular and Molecular Neurobiology. 2021. ↩︎
Espadas I, et al. M1 muscarinic receptor activation protects against alpha-synuclein toxicity. Movement Disorders. 2020. ↩︎